Amicus Therapeutics — FY2023 Earnings Presentation
22 slides from Amicus Therapeutics's earnings presentation, Feb 28, 2024
Slide 1: FY23 Results Conference Call & Webcast
AT T H E F O R E F RO N T O F THERAPIES FOR RARE DISEASES FY23 Results Conference Call & Webcast February 28, 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and c
Slide 3: A Rare Company
A Rare Company A leading biotech company with >$500M of sales projected in 2024 LEVERAGEABLE GLOBAL 2 World Class Clinical Non-GAAP PROFITABILITY COMMERCIAL APPROVED Development Q4 2023 ORGANIZATION THERAPIES Capabilities ACHIEVED >500 EMPLOYEES $399M Combined Peak in 20+ Countries in 2023 Revenue E
Slide 4: Strategic Priorities
2024 Strategic 1 Drive double-digit Galafold® revenue growth of 11-16% at CER1 Priorities A Transformative 2 Execute multiple successful launches of Pombiliti + Opfolda Year Ahead for Amicus Advance ongoing studies to support medical and scientific 3 leadership in Fabry and Pompe diseases 4 Achieve
Slide 5: Galafold (migalastat) Continued Growth
Galafold® (migalastat) Continued Growth Building a leadership position in the treatment of Fabry disease 5
Slide 6: 2023 Galafold Success (as of December 31, 2023)
2023 Galafold Success (as of December 31, 2023) Galafold is the only approved oral treatment option in Fabry disease A unique mechanism of action for Fabry patients with amenable variants $388M 2023 Galafold Revenue 60-65% 17% Share of Treated YoY Growth at CER1 Amenable Patients 2,400+ 35-50% Fabry
Slide 7: Galafold Performance
Galafold Performance Galafold YTD reported revenue growth of +18% to $388M $430M-450M1 Global mix of switch (~43%) and previously $388M untreated patients (~57%)2 $329M Q4 $306M $107M Expect non-linear quarterly growth to continue $261M due to uneven ordering patterns Q3 and FX fluctuations $101
Slide 8: Key Growth Drivers for 2024
Key Growth Drivers for 2024 Building off a strong year with highest patient demand seen in last four years to lay the groundwork for continued double-digit Galafold growth in 2024 Increasing patient identification through ongoing medical education, screening, and improved diagnostics Driving mar
Slide 9: Pombiliti + Opfolda
Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) Potential to establish a new standard of care for people living with late-onset Pompe disease 9
Slide 10: Successful Global Launch of Pombiliti + Opfolda Underway
Successful Global Launch of Pombiliti + Opfolda Underway FY 2023 revenue of $11.6M ($8.5M in Q4 2023) provides strong foundation for 2024 Patient Demand KOL Outreach Access and As of early January 2024 Reimbursement ~120 patients treated with Successfully engaged with Positive interactions commercia
Slide 11: Regulatory and Clinical Updates
Regulatory and Clinical Updates Continuing to build the body of evidence and expand commercial access >10 reimbursement dossiers and multiple regulatory submissions throughout 2024 Ongoing clinical studies in children with late-onset Pompe disease (LOPD) and infantile-onset Pompe disease (IOPD)
Slide 12: Corporate Outlook
Corporate Outlook Delivering on our mission for patients and shareholders 12
Slide 13: FY 2023 Select Financial Results
FY 2023 Select Financial Results 2023 revenue of $399.4M, up 20% at CER, and net loss significantly reduced (in thousands, except per share data) Dec. 31, 2023 Dec. 31, 2022 Product Revenue $399,356 $329,233 Cost of Goods Sold 37,326 38,599 R&D Expense 152,381 276,677 SG&A Expense 275,270 213,041 Ch
Slide 14: Financial Outlook and Path to Profitability
Financial Outlook and Path to Profitability Clear strategy to build our business, advance our portfolio, and achieve profitability Sustain Revenue Successfully Launch Deliver on Growth Pombiliti + Opfolda Financial Goals Focused on disciplined $399M FY23 revenue, expense management +21% YoY growth G
Slide 15: Positioned for Significant Value Creation in 2024
Positioned for Significant Value Creation in 2024 Unlocking the value of two unique commercial therapies in sizeable and growing markets Delivering Clear line of Accelerating sight to full-year total revenue generating non-GAAP1 growth positive profitability cashflow 1 Non-GAAP Net (Loss) Income def
Slide 16: Appendix
Appendix
Slide 17: Appendix I: Reconciliation of Non-GAAP Financial Measures
Appendix | Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) (Unaudited) Years Ended December 31, 2023 2022 2021 Total GAAP operating expenses S$ 439,241 S$ 502,754 S$ 477,482 Research and development: Share-based compensation 21,469 25,089 17,340 Selling, genera
Slide 18: Appendix II: Reconciliation of Non-GAAP Financial Measures
Appendix II Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands, except share and per share amounts) (Unaudited) Three Months Ended Years Ended December 31, December 31, 2023 2022 2023 2022 GAAP net loss S (33,843) S (85,865) S (151,584) S (236,568) Share-based comp
Slide 19: Environmental, Social, & Governance (ESG) Snapshot
Environmental, Social, & Governance (ESG) Snapshot Who We Serve Environmental Our mission is to drive Diversity, Equity, & Management sustainability with our partners by Inclusion (DEI) Committed to producing incorporating Pledge to support a more inclusive culture to impact Programs we Address a ra
Slide 20: FX Sensitivity and Galafold Distribution of Quarterly Sales
FX Sensitivity and Galafold Distribution of Quarterly Sales Impact from Foreign Currency Q4 2023: Currency Variances: Q4 2022 Q4 2023 YoY Variance USD/ EUR 1.021 1.076 5.4% Distribution of Galafold Revenue GBP 1.174 1.241 5.7% by Quarter over Past 5 Years: JPY 0.007 0.007 (4.4%) Q1 Q2 Q3 Q4 5 Year A
Slide 21: Streamlined Rare Disease Pipeline with Focus on Fabry and Pompe
Streamlined Rare Disease Pipeline with Focus on Fabry Disease and Pompe Disease Franchises INDICATION D I S C O V E R Y P R E C L I N I C A L P H A S E 1 / 2 P H A S E 3 R E G U L A T O R Y C O M M E R C I A L FAB RY F RANC H IS E Galafold® (migalastat) Fabry Genetic Medicines Next-Generation Chaper
Slide 22: Thank you
Thank you